Home / Doxorubicin / Sweden
SE ATC L01DB01 · updated 2 Nov 2026
Doxorubicin shortage in Sweden
Is there a Doxorubicin shortage in Sweden?
Yes. As of 2 Nov 2026, 4 Doxorubicin products are reported short in Sweden, the first since 1 Jan 2025. The company estimate for the return is 30 Nov 2026 (latest 30 Jun 2027). Main reason: not stated.
Also short in Canada, Germany, Italy, Ireland, Austria, Belgium, Czechia. All countries.
Affected products in Sweden
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| SE | Doxorubicin Teva 2 mg/ml Injektionsflaska, 1 x 100 ml | Teva Sweden AB | 1 Jan 2025 | 30 Jun 2027 | Not stated |
| SE | Caelyx pegylated liposomal 2 mg/ml Injektionsflaska, 25 ml | Baxter Holding B.V. | 28 Aug 2026 | 31 Dec 2026 | Not stated |
| SE | Zolsketil pegylated liposomal 2 mg/ml Injektionsflaska, 10 ml | Accord Healthcare S.L.U. | 2 Oct 2026 | 30 Nov 2026 | Not stated |
| SE | Caelyx pegylated liposomal 2 mg/ml Injektionsflaska, 10 ml | Baxter Holding B.V. | 21 Oct 2026 | 15 Dec 2026 | Not stated |
Source
Läkemedelsverket (Swedish Medical Products Agency). Official list. Ongoing and announced shortages (restanmälningar) reported by companies; one row per pack.